ABSTRACT OF THE DISCLOSURE

Please add new page 35 to the application containing the abstract of the disclosure as follows:

ABSTRACT OF THE DISCLOSURE

A serine protease inhibitor having the formula (I),

in which

J is $H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-(CHR^2)_p-,$ $(R^{2a}, R^{2b}) N-CO-(CHR^2)_p-$ or $Het-CO-(CHR^2)_p-;$

W is an amino-acid of the formula $-NH-CHR^1-C(O)-$, $-NR^4-CH((CH_2)_qC(O)OR^1)-C(O)-$,

 $-{\rm NR}^4-{\rm CH}\,(\,({\rm CH_2})_{\,q}{\rm C}\,({\rm O})\,{\rm N}\,({\rm R}^{2a},{\rm R}^{2b})\,)\,-{\rm C}\,({\rm O})\,-,$

 $-{\rm NR}^4-{\rm CH}\left(\,\left({\rm CH_2}\right)\,{}_{\rm q}{\rm C}\left({\rm O}\right)\,{\rm Het}\right)\,-{\rm C}\left({\rm O}\right)\,-,$

D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3

Piq, glutanyl or a (C_1-C_6) alkylester thereof;

 \mathbf{E} is $-NR^2-CH_2-$ or the fragment

(CH₂)_t

, which is unsubstituted or substituted

with (1-6C) alkyl, (1-6C) alkoxy or benzyloxy; R^1 is selected form (1-12C) alkyl,

(2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF₃ or halogen, and from

(6-14C) aryl, (7-15C) aralkyl, (8-16C) aralkenyl and (14-20C) (bisary) alkyl, wherein the aryl groups are

unsubstituted or substituted with (1-6C)alkyl,

(3-12C) cycloalkyl, (1-6C) alkoxy, OH, CF₃ or halogen;

 R^2 , R^{2a} and R^{2b} are each independently selected from

H, (1-8C) alkyl, (3-8C) alkenyl, (3-8C) alkynyl,

(3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C) cycloalkyl, (1-6C) alkoxy, CF_3 or halogen, and (6-14C) aryl and (7-15C) aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C) alkyl, (3-6C) cycloalkyl, (1-6C) alkoxy, CF₃ or halogen; R^3 is the same as R^2 or is Het-(1-6C)alkyl; R^4 is H or (1-3C) alkyl; X and Y are CH or N, with the proviso that they are not both N; Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S; m is 1 or 2; p is 1, 2 or 3; q is 1, 2 or 3; t is 2, 3 or 4; or a pharmaceutically acceptable addition salt or

solvate thereof.